Your session is about to expire
← Back to Search
Nasal Insulin for Alzheimer's
Study Summary
This trial will test if administering insulin through the nose can help people with Alzheimer’s by measuring how much insulin is delivered to the brain, as well as any effects on memory or blood levels.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken a new and experimental drug within two months before the screening visit.I have had a seizure in the last five years.I have diabetes, whether I use insulin or not.My medications have been the same for the last 4 weeks.I do not regularly use alcohol, narcotics, or specific medications.I have had a serious stroke in the past.My health condition has been stable for the last 3 months.I haven't had epilepsy, major head injuries, or severe mental health issues in the last 2 years.I am taking warfarin (Coumadin) or dabigatran (Pradaxa).I have used insulin or other diabetes medications in the last 2 months.You have been diagnosed with dementia.
- Group 1: 40 IU Insulin first, then 20 IU Insulin
- Group 2: 20 IU Insulin first, then 40 IU Insulin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the standard dosage of Humulin® R U-100 for most patients?
"20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) is a commonly used medication for treating community acquired pneumonia caused by susceptible strains of streptococcus pneumoniae. It is also effective for managing uncomplicated skin and skin structure infections caused by staphylococcus aureus infections, hospital acquired pneumonia, and type 1 diabetes mellitus."
Is 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) a common dose in other medical trials?
"Currently, there are 96 ongoing clinical trials researching 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) with 20 trials in Phase 3. While many of the clinical trials for 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) are located in Sao Luis, MA, there are 375 locations running studies for 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)."
Has the FDA issued a 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) license?
"While there is some evidence that suggests 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) is safe, it only received a 2 because this medication has not yet been proven effective."
What is the target recruitment for this research project?
"This clinical trial is not currently looking for candidates at this time. The trial was first posted on 7/16/2020 and was most recently edited on 10/28/2022. If you are exploring for other studies, there are currently 634 trials actively looking for patients with cognitive impairment (ci) and 96 trials for 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) admitting participants."
May I sign up for this clinical trial?
"The ideal candidate for this trial is somebody aged 55 to 85 who currently struggles with ci. Furthermore, it is a requirement that potential participants have had no changes to their medical condition or medications for at least 3 and 4 months respectively."
Are geriatric patients being included in this research?
"This trial is only for patients aged 55 to 85. Out of the 661 clinical trials that are available for patients over 65, this one has the most specific age range."
Are new participants being accepted into this clinical trial at present?
"The clinical trial mentioned is not currently recruiting patients, as indicated by the data on clinicaltrials.gov. This particular study was posted on 7/16/2020 and last updated on 10/28/2022. There are however, 730 other trials that are actively looking for candidates."
Share this study with friends
Copy Link
Messenger